Literature DB >> 11339852

The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms.

M J Schwarz1, N Müller, M Riedel, M Ackenheil.   

Abstract

Immunologic findings in schizophrenia have been described for decades, but it was not possible to identify a pathogen until now. Most of these studies report immune abnormalities in a group of the investigated patients, but a distinct subgroup of schizophrenia with immune-related pathology has still not been characterized. In this paper we have integrated the most important immunologic data in schizophrenia research and hypothesize a shift to Th2-like immune reactivity in a subgroup of schizophrenic patients. Besides the immunological abnormalities, this subgroup is further characterized by more pronounced negative symptoms and poor therapy outcome. There is evidence that this subgroup might be caused by a prenatal viral infection. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11339852     DOI: 10.1054/mehy.2000.1203

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  36 in total

1.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

Review 2.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

3.  Converging evidence implicates the abnormal microRNA system in schizophrenia.

Authors:  Fuquan Zhang; Yong Xu; Yin Yao Shugart; Weihua Yue; Guoyang Qi; Guozhen Yuan; Zaohuo Cheng; Jianjun Yao; Jidong Wang; Guoqiang Wang; Hongbao Cao; Wei Guo; Zhenhe Zhou; Zhiqiang Wang; Lin Tian; Chunhui Jin; Jianmin Yuan; Chenxing Liu; Dai Zhang
Journal:  Schizophr Bull       Date:  2014-11-26       Impact factor: 9.306

Review 4.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

Review 5.  Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia.

Authors:  Anna M Fineberg; Lauren M Ellman
Journal:  Biol Psychiatry       Date:  2013-02-12       Impact factor: 13.382

6.  Markers of inflammation in schizophrenia: association vs. causation.

Authors:  Peter Manu; Christoph U Correll; Martien Wampers; Alex J Mitchell; Michel Probst; Davy Vancampfort; Marc De Hert
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

Review 7.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

9.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

Review 10.  A review of anti-inflammatory agents for symptoms of schizophrenia.

Authors:  William R Keller; Lionel M Kum; Heidi J Wehring; Maju Mathew Koola; Robert W Buchanan; Deanna L Kelly
Journal:  J Psychopharmacol       Date:  2012-11-13       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.